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Abstract
In clinical exome and genome sequencing, there is potential for the recognition and reporting of
incidental or secondary findings unrelated to the indication for ordering the sequencing but of
medical value for patient care. The American College of Medical Genetics and Genomics
(ACMG) recently published a policy statement on clinical sequencing, which emphasized the
importance of disclosing the possibility of such results in pretest patient discussions, clinical
testing, and reporting of results. The ACMG appointed a Working Group on Incidental Findings in
Clinical Exome and Genome Sequencing to make recommendations about responsible
management of incidental findings when patients undergo exome or genome sequencing. This
Working Group conducted a year-long consensus process, including review by outside experts,
and produced recommendations that have been approved by the ACMG Board. Specific and
detailed recommendations, and the background and rationale for these recommendations, are
described herein. We recommend that laboratories performing clinical sequencing seek and report
mutations of the specified classes or types in the genes listed here. This evaluation and reporting
should be performed for all clinical germline (constitutional) exome and genome sequencing,
including the ‘normal’ of tumor-normal subtractive analyses in all subjects, irrespective of age, but
excluding fetal samples. We recognize that there are insufficient data on clinical utility to fully
support these recommendations and we encourage the creation of an ongoing process for updating
these recommendations at least annually as further data are collected.
Keywords
secondary findings; incidental findings; genome; genomic medicine; personalized medicine;
whole-exome; whole-genome; sequencing
INTRODUCTION
Exome and genome sequencing (collectively referred to in this paper as clinical sequencing)
are rapidly being integrated into the practice of medicine,1,2 The falling price of sequencing,
coupled with advanced bioinformatics capabilities, is creating opportunities to use
sequencing in multiple medical situations, including the molecular characterization of rare
diseases, the individualization of treatment (particularly in cancer), pharmacogenomics,
preconception/prenatal screening and population screening for disease risk.3,4 In all of these
applications, there is potential for the recognition and reporting of incidental (or secondary)
findings, which are results that are not related to the indication for ordering the sequencing
but that may nonetheless be of medical value or utility to the ordering physician and the
patient. Considerable literature discusses the utility and ethics of reporting incidental
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findings discovered in the course of research,5–9 but relatively little has been written about
doing so in the clinical context.10–14 Last year, the American College of Medical Genetics
and Genomics (ACMG) published a policy statement related to clinical sequencing15 that
emphasized the importance of secondary or incidental results in pretest patient discussions,
clinical testing, and reporting of results. Here, we provide the recommendations of the
ACMG Working Group on Incidental Findings in Clinical Exome and Genome Sequencing
(hereafter referred to as the Working Group). These recommendations have been approved
by the Board of the ACMG.
PROCESS
The chairs of the Working Group were appointed in November, 2011 and a written charge to
the Working Group was approved by the ACMG Board of Directors in January, 2012. The
Board charged this Working Group with evaluating the utility of making recommendations
for analyzing and reporting incidental findings from sequencing in the clinical context. The
Working Group was asked to generate an initial list of genes and categories of variants to be
reported as incidental findings. Working group members were appointed and approved by
the ACMG Board in January, 2012 and met weekly by teleconference between January and
September, 2012 and by email throughout the development of this manuscript. The Working
Group began by establishing general processes for accomplishing its charge. We decided to
consider both broad categories of disorders as well as specific genes. The initial list of genes
considered by the Working Group was derived from the genes evaluated in Green et al.10
and supplemented by a provisional list of genes13 being evaluated at the University of
Washington for return of results.
The Working Group presented its principles and plans, and solicited feedback at an Open
Forum at the ACMG Annual Meeting in March, 2012. These principles and plans were
further developed based on feedback from ACMG members, and were provisionally
reviewed by the ACMG Board in May, 2012 and again in November, 2012. A group of 20
additional experts was nominated by the Working Group members in May, 2012. Fifteen
agreed to serve as external reviewers, and feedback from the additional reviewers was
solicited in conference calls in June, 2012 and by email in January, 2013. The
recommendations and this manuscript were revised based on this feedback. Final approval
by the ACMG Board was provided on March 19, 2013.
The Working Group used the ACMG policy statement entitled “Points to Consider in the
Clinical Application of Genomic Sequencing”15 as a starting point for its deliberations. That
document includes a definition of clinical sequencing, describes the indications for such
testing, and provides guidance on pre-test considerations, results reporting, genetic screening
issues, and post-test considerations. Those issues were not revisited by this Working Group




This term refers to the individual practitioner or clinical team who has direct contact or is
responsible for direct contact with the patient and family. The clinician should be properly
trained and prepared in genetics and genomics with an understanding of genetic counseling,
pedigree analysis and risk assessment to provide pre-test and post-test patient care
associated with clinical sequencing.15
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This term refers to the entity that takes responsibility for analysis, interpretation, and report
generation of sequencing performed for clinical purposes. The Working Group recognizes
that in some cases, one entity may generate the raw sequencing data and another may further
evaluate and interpret the sequence, consider additional or confirmatory testing and issue a
clinical report. The latter is the focus of these recommendations.
Patient
This term is used to describe adults who undergo clinical sequencing and are competent to
make their own health care decisions. The term, as used here, also refers to parents of minor
children or guardians of decisionally-impaired adults who may undergo this testing. In cases
where young children or decisionally-impaired adults undergo sequencing, pre- and post-test
counseling and consent of parents or guardians on behalf of the minor or decisionally
impaired adult should occur, but teenagers and mildly decisionally-impaired adults should
not be excluded from these discussions and assent should be sought in appropriate cases.
Primary Finding
This term is used to describe pathogenic alterations in a gene or genes that are relevant to the
diagnostic indication for which the sequencing was ordered (e.g., a mutation in MECP2 in a
girl with loss of developmental milestones).
Incidental Finding
This term has been used in a variety of clinical and research contexts to indicate unexpected
positive findings. Other terms have been used to describe these findings, particularly when
they are sought after (rather than being unexpectedly discovered). These terms include
“serendipitous and iatrogenic” findings,16 “non-incidental secondary findings”17
“unanticipated findings”,18 and “off-target results”.1 We use “incidental findings” in this
paper to indicate the results of a deliberate search for pathogenic or likely pathogenic
alterations in genes that are not apparently relevant to a diagnostic indication for which the
sequencing test was ordered.
WORKING GROUP CONSIDERATIONS
The Clinical Utility of Incidental Findings
Some have argued that incidental findings should not be reported at all in clinical
sequencing until there is strong evidence of benefit, while others have advocated that
variations in any and all disease-associated genes could be medically useful and should be
reported.19 The Working Group acknowledged that there was insufficient evidence about
benefits, risks and costs of disclosing incidental findings to make evidence-based
recommendations. Nonetheless, based upon available evidence and clinical consensus
among its members, the Working Group determined that reporting some incidental findings
would likely have medical benefit for the patients and families of patients undergoing
clinical sequencing. In reaching this consensus we recognized that our clinical experience
has been derived largely from patients with disease symptoms or positive family histories.
As additional evidence accrues on the penetrance of these variants among persons without
symptoms or family history, these recommendations will be expected to evolve.
The Working Group elected to present recommendations in the form of a “minimum list” of
incidental findings to report from clinical sequencing. While all of the disorders are rare,
most of these genes and variant categories were selected because they are associated with
the more common of the monogenic disorders, and because the Working Group reached a
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consensus that they met criteria described below. The Working Group specified a set of
disorders, the relevant associated genes and certain categories of variants that should be
reported, based on a consensus-driven assessment of clinical validity and utility. Where
evidence was lacking, the Working Group drew upon the clinical judgment of its members.
The Working Group acknowledged that its membership (and the ad hoc reviewers listed in
the Appendix) were not always in complete agreement, could not fully represent the
opinions of others in the field, and did not have detailed knowledge of all of the conditions
that were considered.
The Working Group tried to include conditions on the list where confirmatory approaches
for medical diagnosis would be available, although we recognized that this standard could
not be met for all of the conditions listed. The Working Group prioritized disorders where
preventative measures and/or treatments were available and disorders in which individuals
with pathogenic mutations might be asymptomatic for long periods of time. In most cases,
the Working Group recommended restricting the variants to be reported as incidental
findings to those that meet criteria for reporting as Pathogenic (noted as “Sequence variation
is previously reported and is a recognized cause of the disorder” or “Sequence variation is
previously unreported and is of the type which is expected to cause the disorder”.20 These
were chosen because we recognized the challenge of attempting to report and interpret
variants of unknown significance as incidental findings. Given the low prior probability that
an individual has a monogenic disorder that could be identified incidentally through exome
or genome sequencing, we recommended that only variants with a higher likelihood of
causing disease should be reported as incidental findings although we recognize that there
are limited data available in many cases to make this assessment.
While some definitions of incidental findings allude to findings that are discovered without
actually searching for results, this was not the basis for our recommendations. The Working
Group recommended that the laboratory actively search for the specified types of mutations
in the specified genes listed in these recommendations.
In making these recommendations, the Working Group only addressed the circumstance in
which the report of incidental findings would be delivered to the clinician who ordered the
clinical sequencing. It was expected that this clinician would contextualize any incidental
findings for the patient in light of personal and family history, physical examination, and
other relevant findings. This places responsibility for managing incidental findings with the
ordering clinician, as we believe that the clinician-patient interaction is the appropriate place
for such information to be explained and discussed.21,22
Limitations and Interpretation of Incidental Findings
The Working Group recognized that when a laboratory evaluates genes for the specified
categories of variants recommended here as incidental findings, the analysis may not be
technically equivalent to examining these genes as a primary finding. For example,
sequencing could have areas of diminished or absent coverage in the genes examined for
incidental findings that would be filled in by Sanger sequencing or other supplementary
approaches if the gene were being evaluated for a primary indication. In addition, while
genome sequencing can provide increasingly reliable information on copy number variation
and translocations, exome sequencing is currently less reliable, and neither technology can
be used to measure tandem repeat size accurately. For these reasons, we did not include
some disorders where structural variants (e.g., translocations and inversions), repeat
expansions, or copy number variations are the primary cause, and have not recommended
that laboratories utilize orthogonal techniques to search for these variants in the genes
named in the minimum list. Thus, the Working Group recommended that laboratories
evaluate these genes for the specified categories of variants to the extent that the available
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data from the genome or exome sequence allow. We did not recommend that labs insure a
depth of coverage for these genes equivalent to molecular testing for a primary indication.
Given these recommendations, the Working Group was concerned that a negative incidental
findings report could be misconstrued by clinicians or patients as an assurance of the
absence of a pathogenic variant, which is not always the case. To address this, we
recommended that the report of incidental findings issued by the laboratory include distinct
language differentiating the quality of the incidental findings report from the quality of
molecular testing that would be conducted for a primary indication.
On the other hand, when there is a positive incidental finding, the Working Group
recommended that laboratories review available literature and databases at the time of the
sequence interpretation to insure there is sufficient support for pathogenicity before
reporting a variant. The Working Group recognized that there is no single database currently
available that represents an accurately curated compendium of known pathogenic variants,
nor is there an automated algorithm to identify all novel variants meeting criteria for
pathogenicity. Therefore, evaluation and reporting of positive findings in these genes may
require significant manual curation.
Patient Preferences and Incidental Findings
Standards for molecular testing in clinical genetics have largely evolved around testing an
affected individual or suspected carrier for a mutation or testing an unaffected relative of a
patient with a known mutation. In these situations, extensive pre-test counseling can
ascertain with confidence the preference of the individual to be tested in terms of choosing
whether or not to obtain a specific genetic test for a specific hereditary condition. By
contrast, after clinical sequencing for a specific indication, the patient has already undergone
an assay of all other disease-associated genes. In order to respect preferences in the same
manner as with targeted testing, the patient whose exome or genome is sequenced would
have to undergo an extensive, and possibly overwhelming, amount of genetic counseling for
numerous conditions unrelated to the primary indication for sequencing. This will become
impractical as clinical sequencing becomes more common and both its lack of
standardization and its application to patients of all circumstance might result in deeply
varying levels of truly informed preference setting.
Even if preferences about receiving a limited set of incidental findings were accurately
explained, carefully noted and clearly communicated to the laboratory, the laboratory would
have to mask the informatics analysis of specific genes or ignore findings of potential
medical importance in order to honor those preferences. All of this may be feasible in an
environment where the laboratory is an interactive partner in the clinical assessment of a
patient by clinicians skilled in genetics and genetic counseling, but will become increasingly
unwieldy as clinical sequencing becomes more common and more commonly ordered by
clinicians with varying levels of ability and experience in genetic counseling. Based upon
these considerations, the Working Group did not favor offering the patient a preference as to
whether or not to receive the minimum list of incidental findings described in these
recommendations. We recognize that this may be seen to violate existing ethical norms
regarding the patient’s autonomy and “right not to know” genetic risk information.
However, in selecting a minimal list that is weighted toward conditions where prevalence
may be high and intervention may be possible, we felt that clinicians and laboratory
personnel have a fiduciary duty to prevent harm by warning patients and their families about
certain incidental findings and that this principle supersedes concerns about autonomy, just
as it does in the reporting of incidental findings elsewhere in medical practice. The Working
Group therefore recommended that whenever clinical sequencing is ordered, the ordering
clinician should discuss with the patient the possibility of incidental findings, and that
laboratories seek and report findings from the list described in the Table without reference to
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patient preferences. Patients have the right to decline clinical sequencing if they judge the
risks of possible discovery of incidental findings to outweigh the benefits of testing.
Incidental Findings in Children
The standards for predictive genetic testing in clinical genetics recognize a distinction
between providing results to adults and providing results to children and adolescents, with
consistent recommendations that predictive testing for adult-onset diseases not be offered to
children.23–25 However, these recommendations can be inconsistent with the general
practice of respecting parental decision-making about their children’s health, and questions
have been raised about the sustainability of these standards in an era of comprehensive
genomic testing.26 One of these recent policy statements noted “…results from genetic
testing of a child may have implications for the parents and other family members. Health
care providers have an obligation to inform parents and the child, when appropriate, about
these potential implications.”24 This statement suggests an important consideration in the era
of genomic medicine since after sequencing a child for a primary indication, it becomes
relatively easy for a laboratory to report a limited number of variants for conditions that
could be medically important to that child’s future or to the rest of the family.
The Working Group recognized that this is a transitional moment in the adaptation of
genomic medicine where the parents of children undergoing sequencing do not have ready
access to inexpensive, readily interpretable exome or genome sequencing in order to obtain
personal risk information for the conditions on our minimum list. In the future, where
parents might all have such access, the identification of an adult-onset disease variants in
their children could be restricted. But at this moment in the evolution of clinical sequencing,
an incidental finding relevant to adult disease that is discovered and reported through
clinical sequencing of a child may be the only way in which that variant will come to light
for the parent. As with the argument against preferences, the Working Group felt that
masking or tailoring the reporting of such information according to the age of the patient
could place an unrealistic burden upon laboratories facing increasing volumes of clinical
sequencing. The Working Group also felt that the ethical concerns about providing children
with genetic risk information about adult-onset diseases were outweighed by the potential
benefit to the future health of the child and the child’s parent of discovering an incidental
finding where intervention might be possible. Therefore, the Working Group recommended
that recommendations for seeking and reporting incidental findings not be limited by the age
of the person being sequenced.
Circumstances Not Addressed in these Recommendations
The Working Group elected not to address a number of issues related to incidental findings
in clinical sequencing. Conditions that were part of routine newborn screening (NBS) were
excluded as they have their own assessment criteria and are applied in a specific public
health framework. Similarly, these recommendations address incidental findings sought and
reported during clinical sequencing for a specific clinical indication but do not address
preconception sequencing, prenatal sequencing, newborn sequencing or sequencing of
healthy children and adults. In particular, the issues associated with genomic sequencing in
healthy individuals of any age will become increasingly salient as costs decline and
informatics interpretation algorithms improve, but the value of population screening for
prevention and health promotion raises complex questions of potential benefits as well as
downstream risks and costs that will need considerably more data to resolve.27–30 We
acknowledged but did not address the possibility that clinical sequencing may be ordered by
specialists who may not feel comfortable discussing incidental findings pertaining to another
organ system, thus generating additional consultations and medical costs. We elected not to
consider questions of data ownership or the legal ramifications of returning or withholding
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raw sequencing results from families that request these. We also did not address issues of
patents in making these recommendations or any of the issues associated with duty to
recontact ordering clinicians (or patients) and update the interpretation of their incidental
findings.31 We have not addressed the implications of including incidental findings in
laboratory reports that will become part of the patient’s health record and the potential for
discrimination that could arise from this circumstance. We recognize that laboratories that
adopt these recommendations may add significant costs to at least some of their sequencing
reports with primer design and Sanger confirmation of positive findings, evidence review,
report generation and sign-out. We do not know the implications that this may have on
reimbursement for clinical sequencing.
There is an active debate about the return of incidental findings in genomic research, and
recommendations for this setting are evolving. While we acknowledge and hope that
investigators find our process and these recommendations useful in their attempts to design
thresholds and lists for the return of genomic findings to research participants, we did not
design this list for that purpose. The Working Group has designed these recommendations
for the situation in which a clinician orders exome or genome sequencing for a specific
clinical indication. In this circumstance, a laboratory report will be returned to that clinician,
who will ideally be in a position to integrate such findings with the medical and family
history and the physical examination, taking into account the psychological state of the
patient and the patient’s family. While we recognize that this ideal may not always be
realized, this is nonetheless a very different scenario than the disclosure of sequence
information outside of the medical care system. The return of incidental findings discovered
in the course of a clinical laboratory investigation is consistent with such practices in other
disciplines of medicine.
RECOMMENDATIONS
1. Constitutional mutations found in the genes on the minimum list (see Table) should
be reported by the laboratory, regardless of the indication for which the clinical
sequencing was ordered.
a. Additional genes may be analyzed for incidental (secondary) variants, as
deemed appropriate by the laboratory.
b. Incidental (secondary) variants should be reported regardless of the age of
the patient.
c. Incidental (secondary) variants should be reported for any clinical
sequencing conducted on a constitutional (but not tumor) tissue. This
includes the normal sample of a tumor-normal sequenced dyad and
unaffected members of a family trio.
2. The Working Group recommends that laboratories seek and report only the types of
variants within these genes that we have delineated (see Table).
a. For most genes, only variants that have been previously reported and are a
recognized cause of the disorder or variants that are previously unreported
but are of the type which is expected to cause the disorder, as defined by
prior ACMG guidelines,20 should be reported.
b. For some genes, predicted loss of function variants are not relevant (e.g.,
COL3A1 and most hypertrophic cardiomyopathy genes).
c. For some genes (e.g., APOB), laboratories should only report variants for
certain conditions.
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3. It is the responsibility of the ordering clinician/team to provide comprehensive pre-
and post-test counseling to the patient.
a. Clinicians should be familiar with the basic attributes and limitations of
clinical sequencing.
b. Clinicians should alert patients to the possibility that clinical sequencing
may generate incidental findings that could require further evaluation.
c. Given the complexity of genomic information, the clinical geneticist
should be consulted at the appropriate time that may include ordering,
interpreting, and communicating genomic testing.
4. These recommendations reflect limitations of current technology, and are therefore
focused on disorders that are caused by point mutations and small insertions and
deletions, not those primarily caused by structural variants, repeat expansions, or
copy number variations.
5. The Working Group recommends that the ACMG, together with content experts
and other professional organizations, refine and update this list at least annually.
DISCUSSION
The ACMG recommends that for any evaluation of clinical sequencing results, all of the
genes and types of variants in the Table should be examined and the results reported to the
ordering clinician. The conditions listed in the Table are those that the Working Group and
external reviewers considered most likely to be verifiable by other diagnostic methods and
amenable to medical intervention based on current evidence and the clinical consensus of
the Working Group members. Reporting these incidental findings to the ordering clinician
will offer the clinician, or an appropriate consulting clinician, the opportunity to re-evaluate
the patient’s personal and family history and consider appropriate surveillance or
intervention for patients and their family members who are deemed to be at increased risk
for these conditions. These recommendations should be understood to represent a minimum
list that is a starting point for the selection and reporting of incidental findings, fully
acknowledging that as additional evidence and expertise are applied, these recommendations
will require ongoing modification. The ACMG recognizes that laboratories may need to take
some time to implement these recommendations.
For most of the recommended genes, only variants that have been previously reported and
are a recognized cause of the disorder or variants that are previously unreported and are of
the type which is expected to cause the disorder have been recommended for analysis and
reporting, and an argument could be made for the examination and reporting of a broader
range of novel variation predicted informatically to be of possible significance. However,
because informatics tools are still unreliable predictors of variant impact, particularly for
missense variants, and because incidental findings are, by definition, identified in persons
outside of the clinical indication for testing, these patients are at a low prior probability of
being affected by the conditions in the Table. The conditions and variant thresholds we
selected for reporting incidental findings have therefore been set to try to maximize the
benefits (increasing the likelihood of true positive results) and minimize the harms
(decreasing the likelihood of false positive results).
There is concern that incidental variant reporting could be misinterpreted as an exhaustive
evaluation of all variation within the genes on this list. These recommendations should not
be construed as an expectation that the laboratory comprehensively assess these genes for all
variants, but rather that the laboratory evaluate the sequence data on these genes that are
generated in the course of routine clinical sequencing. There is potential for confusion and
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even harm to patients if the clinician misunderstands these limitations of the incidental
findings report. For example, if incidental findings are returned without identification of
mutations for any of the cancer susceptibility syndromes, and it later comes to light that the
patient has a family history suggestive of a Mendelian cancer susceptibility syndrome, the
patient or other family members might incorrectly consider themselves to have been “tested”
and found to be “negative.” In fact, a novel missense mutation that may or may not be
causative of the disorder, could be segregating with affected family members may
(appropriately) not have been included in the report of incidental findings. An analogous
situation has been noted with false negative findings in newborn screening.32 To insure that
these considerations are properly presented to the clinicians, we recommend that
laboratories develop an appropriate reporting metric that will make clear the extent of the
evaluation that has been conducted. This will allow clinicians to consider the sensitivity of
the analysis when making clinical assessments and will help avoid over-interpretation of a
negative incidental (secondary) variant analysis.
All of these considerations should be incorporated into an incidental or secondary results
report that provides clinicians with a clear summary of the analysis that was performed, the
depth of coverage and other quality metrics, and any findings. We estimate from limited
amount of published data33 that approximately 1% of sequencing reports will include an
incidental variant from the Table. As recommended in the ACMG policy statement on
clinical sequencing, the clinician ordering these tests is responsible for providing or ensuring
the provision of pretest counseling so that the patient is aware of not only the implications
and limitations of the primary testing, but also the analysis that is being performed for
incidental findings. The clinician should also provide post-test counseling and medical
follow-up as described in the prior ACMG policy statement on Clinical Application of
Genomic Sequencing.15 The informed consent process for clinical sequencing should follow
the forthcoming guideline from the ACMG.
The return of incidental findings to parents of minor children who undergo clinical
sequencing presents difficult issues. The Working Group felt it best not to place arbitrary
age restrictions or limitations on the return of incidental (secondary) variants since the
variants would likely have implications for others in the family. For example, the
sequencing of a child and the discovery of incidental findings that increase the risk of adult-
onset cancer predisposition may be medically important to one of the parents of that child.
In this scenario, the result has been generated and is fully available. To mask or withhold the
incidental finding is to state that the child’s right not to know supersedes the parent’s
opportunity to discover a life-threatening risk factor. We recognize that this
recommendation differs from those developed around candidate gene testing. There are
legitimate concerns about whether pediatricians should be asked to receive and manage
results pertaining to adult-onset conditions and about the psychological impact of such
information on the family. We further acknowledge that there are groups proposing to avoid
this issue when sequencing children by sophisticated masking of off-target genes, making
them unavailable for evaluation.34 Nonetheless, we believe that sequencing creates a
different calculus than that which was envisioned with predictive testing for a familial
condition. In the absence of clarifying data about the actual harms of learning about adult-
onset conditions in children, or the actual benefits to parents who might learn previously
unsuspected risk information through sequencing of their child, we have recommended
disclosure of the conditions, genes and variants listed in the Table for both adults and
children who undergo clinical sequencing.
The Working Group recognizes that there is a wide range of opinions about what constitutes
incidental findings in clinical sequencing and how they should be managed. On one side are
genetic libertarians who feel that patients have the right to full and complete accounting of
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all possible risks conveyed by both established and novel variants, or even variants of
unknown significance in disease genes. On the other side are genetic empiricists who
believe that there is insufficient evidence about the penetrance of most pathogenic variants
in the general population to warrant the sharing of any incidental findings, and that it is
irresponsible to create the psychological burdens of being a “patient in waiting”35 or to
expose patients to iatrogenic harm of possibly unnecessary surveillance or diagnostic
testing. An argument is sometimes made that if the search for incidental findings were
warranted, then it would follow that broad-based population screening should be advocated.
In reality, seeking and reporting of incidental findings represents a form of “opportunistic
screening”36 that has a long history in clinical medicine. When patients complain of
symptoms in the digestive system, the well-trained physician examines cardiac and
respiratory systems as well, both for clues to a multi-system disease and to incidentally
discover any unrelated signs. When radiographs are read for a particular anatomical focus,
the radiologist scans the entire radiograph and also reports on abnormal findings in regions
not indicated as the primary reason for the study. In these situations, unlike population
screening with its requirement of extensive cost and infrastructure, the patient has already
presented to the medical care system, has been evaluated and is under the care of a clinician.
Moreover, much of the cost of the study and any associated risk has already been sustained
for the primary indication, lowering the cost/risk-to-benefit ratio for the discovery of
incidental findings.
The Working Group recognizes that many of the concerns, debates, and widely varying
opinions described here are the consequence of a lack of empiric data. We recognize this
critical limitation, but nonetheless determined that an initial set of recommendations was
appropriate at this time. To address the issue of a lack of data, the Working Group
encourages prospective research on incidental or secondary findings and the development of
a voluntary national patient registry to longitudinally follow individuals and their families
who receive incidental or secondary findings as part of clinical sequencing and document
the benefits, harms and costs that may result.
In summary, the Working Group has recommended that when a report is issued for clinically
indicated exome and genome sequencing, a minimum list of conditions, genes and variants
should be routinely evaluated and reported to the ordering clinician who can place them into
the context of that patient’s medical and family history, physical examination and other
laboratory testing. We have recommended that these findings be reported without seeking
preferences from the patient and family and without limitation due to the patient’s age. In
this, we attempt to strike a balance between the positions of genetic libertarians and the
genetic empiricists, guided by the currently available scientific literature, clinical
experience, the consensus of our Working Group members and the traditions of clinical
medicine. The Working Group recognizes that this list should, and will, evolve as further
empirical data are collected on the actual penetrance of these variants, and on the health
benefits and costs that might follow from their disclosure as incidental findings.
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